© 2020 MJH Life Sciences and Neurology Live. All rights reserved.
© 2020 MJH Life Sciences™ and Neurology Live. All rights reserved.
September 29, 2020
Neuropsychiatric symptoms are now recognized as hallmarks of dementia and are important targets for the development of effective treatments.
With more than a dozen available therapies, disease-modification in multiple sclerosis is entering a new era of development.
Several agents are currently in development geared at the relief of off-time for patients with Parkinson.
Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.
A novel mesenchymal stem cell therapy produced intriguing phase II data and has moved into a randomized, pivotal phase III clinical trial.
Physicians offer perspectives on newly approved products to prevent migraine.